INSERM U1242 Oncogenesis Stress Signaling - SPECIAL SEMINAR
Integrative discovery of non-canonical neoantigens: emerging opportunities and challenges for cancer immunotherapy Dr. Léa PROCHASSON PharmD and molecular biologist Curie Institute - PARIS Unité « Dynamique de l’information Génétique, bases fondamentales et cancer » (UMR3244) Equipe: ARN non codant, épigénétique et fluidité des génomes Abstract The clinical success of cancer immunotherapy relies on the identification of tumour-specific antigens capable of eliciting effective T-cell responses. However, canonical mutation-derived neoantigens remain challenging targets because of their limited immunogenicity, patient specificity, and heterogeneous HLA presentation. In contrast, the non-canonical proteome, generated through the translation of alternative open reading frames (ORFs) within non-coding transcripts, represents a promising and largely unexplored source of tumour antigens. Here, we developed an integrative pipeline for the discovery and validation of shared non-canonical neoantigens in pancreatic cancer. By combining transcriptome-wide k-mer analysis, ribosome profiling, immunopeptidomics, and functional immunogenicity assays, we identified 14 non-canonical neoantigens across primary and metastatic tumors, presented by several common HLA alleles (HLA-A02:01, -A01:01 and -A24:02). Their therapeutic potential was further assessed through MHC-binding, T-cell activation, and peptide-specific T-cell receptor (TCR) screening using naïve CD8+ T cells from healthy donors.
- Date
- mardi 20 octobre 2026, de 11h00 à 12h00
- Lieu
- Centre de Lutte Contre le Cancer Eugène Marquis, Avenue de la Bataille Flandres Dunkerque, 35043 Rennes
- Organisateur
- UMR INSERM 1242 Oncogenesis Stress Signaling (OSS)
Voir cet événement sur DEMAiN app
Information issue de la base ouverte DATAtourisme.